Atrial natriuretic factor inhibits hypertonic saline-mediated decreases in renal hemodynamics. The present study in the anesthetized dogs was designed to test the hypothesis that atrial natriuretic factor (ANF) attenuates whole kidney tubuloglomerular feedback (TGF) mediated decreases in renal blood flow (RBF) and glomerular filtration rate (GFR) produced by hypertonic saline (HS). Secondly, as adenosine (AD) has been implicated as a metabolic mediator of TGF, we also hypothesized that ANF would antagonize the renal actions of AD. To test this hypothesis, RBF and GFR were assessed in response to hypertonic saline (HS, 16%, i.r.) or adenosine (AD, 0.1 mol/min, i.r.) in the presence and absence of exogenous ANF (100 ng/kglmin, i.r.). ANF attenuated HS-mediated reductions in GFR (HS, -39.6 9.8 mI/mm vs. HS + ANF, -14.3 4.5 mI/mm, P < 0.05) and in RBF (HS, 35 mI/mm vs. HS + ANF, -5 22 mI/mm, P < 0.05). GFR was reduced by AD (-9.2 3.0 mI/mm, P < 0.05), but maintained by AD + ANF (-0.4 2.0 mI/mm, NS). A transient adenosine-mediated vasoconstnction was attenuated by ANF (AD, -54.5 3.6 mI/mm vs. AD + ANF, -3.7 3.1 mI/mm, P < 0.005). We conclude that ANF at pharmacologic concentrations attenuates at the whole kidney level hypertonic saline and adenosine-mediated reductions in RBF and GFR. Tubuloglomerular feedback is a renal blood flow autoregulatory mechanism which participates in the control of glomerular filtration rate (GFR) [1] [2] [3] . Activation of TGF may occur in response to an increase in delivery of sodium and chloride to the macula densa. Activation results in a renal hemodynamic response characterized by a decrease in renal blood flow secondary to an increase in afferent arteriolar resistance and a subsequent decrease in GFR secondary to a decrease in gbmerular hydrostatic pressure. The sensitivity of TGF in response to increases in solute load to the macula densa is decreased in acute and chronic states of intravascular volume expansion. This is in contrast to enhanced sensitivity in states of volume depletion.
Tubuloglomerular feedback is a renal blood flow autoregulatory mechanism which participates in the control of glomerular filtration rate (GFR) [1] [2] [3] . Activation of TGF may occur in response to an increase in delivery of sodium and chloride to the macula densa. Activation results in a renal hemodynamic response characterized by a decrease in renal blood flow secondary to an increase in afferent arteriolar resistance and a subsequent decrease in GFR secondary to a decrease in gbmerular hydrostatic pressure. The sensitivity of TGF in response to increases in solute load to the macula densa is decreased in acute and chronic states of intravascular volume expansion. This is in contrast to enhanced sensitivity in states of volume depletion.
Recent studies have suggested a modulating role for pharmacologic concentrations of atrial natriuretic factor (ANF) in the control of TGF. Huang and Cogan have reported in microperfusion studies that pharmacologic concentrations of ANF may attenuate TGF-mediated decreases in single nephron glomerular filtration (SNGFR) [4] . Such studies confirm earlier reports of Briggs and Schnermann in which crude atrial extracts Received for publication June 9, 1989 and in revised form March 16, 1990 Accepted for publication March 20, 1990 © 1990 by the International Society of Nephrology blunted TGF-mediated decreases in SNGFR [5, 6] . More recent studies by Polbock and Arendshort suggest that these earlier studies employing artificial tubular fluid for microperfusion overestimated the inhibitory action of ANF upon TGF [7] . To date, therefore, the significance of these microperfusion studies upon the modulating action of pharmacologic concentrations of ANF upon whole kidney TGF-mediated control of renal blood flow (RBF) and GFR are unknown. Furthermore, potential mechanism(s) by which ANF may modulate the renal hemodynamic response to TGF activation has also not been investigated.
The objective of the present investigation was twofold. The first objective was to determine if ANF, infused into the renal artery at pharmacologic concentrations in anesthetized dogs, attenuates the RBF and GFR reductions to renal artery infusion of hypertonic saline. Although micropuncture was not employed in the current study, previous investigators have demonstrated that hypertonic saline may serve as a stimulus to TGF at the whole kidney level to decrease RBF and GFR [6, 8] . The second objective of the present study was to determine if renal artery infusion of ANF attenuates the transient renal vasoconstriction and the more prolonged decrease in GFR to renal artery infusion of adenosine, a putative metabolic mediator of TGF [9] . Thus, these studies were designed to test the hypothesis that pharmacologic concentrations of exogenous ANF attenuates HS-mediated decreases in renal blood flow and glomerular filtration rate as well as the renal action of adenosine.
Methods
Studies were performed on male mongrel dogs weighing 16 to 28 kg. Experiments were performed on two groups of dogs: Group 1 (N = 12) consisted of normal dogs receiving intrarenal hypertonic saline (HS), and Group 2 (N = 12) consisted of dogs receiving intrarenal adenosine (AD).
On the day of the acute experiments all dogs were anesthetized with pentobarbital (30 mg/kg, i.v.), and supplemented with small amounts as necessary. After endotracheal intubation. animals were ventilated using a Harvard respirator. Both fernoral arteries and one femoral vein were cannulated and PE 240 polyethylene tubing inserted. One femoral artery was cannubated to permit blood sampling for determining plasma levels of inulin and electrolytes. To avoid perturbation of renal hernodynamics during blood sampling, care was taken to place the tip of this catheter distal to the renal artery, advancing it only 5 to 8 cm proximal to the inguinal ligament. The other femoral artery was cannulated with the catheter tip placed in the thoracic aorta for continuous arterial blood pressure measurements. A femoral vein was cannulated for infusion of inulin to maintain a plasma level of 50 nglml. The left kidney was exposed through a retroperitoneal flank incision. In the event two renal arteries supplied this kidney, the incision was closed to prevent evaporative fluid loss, and the right kidney was exposed through a separate flank incision. The corresponding ureter was then cannulated with PE 240 polyethylene tubing for timed urine collections. An electromagnetic flow probe (Carolina, King, North Carolina, USA) was placed around the renal artery and connected to a flow meter for continuous measurement of renal blood flow. Renal blood flow and arterial blood pressure were simultaneously recorded on a Gould model 2200 strip-chart recorder. Two curved 23 gauge needles attached to PE 50 polyethylene tubing were inserted into the renal artery proximal to the flow probe for administration of the following solutions depending on the protocol: hypertonic saline, adenosine, atrial natriuretic factor (ANF), or vehicle. Patency was maintained in these catheters by infusion of isotonic saline (protocol 1) or isotonic dextrose (protocol 2) at a rate of 0.1 mi/mm. After surgical preparation, the animals were allowed to stabilize for 60 minutes prior to initiating the protocols. Each protocol consisted of four observation periods: 1) baseline, 2) control, 3) HS or AD infusion, and 4) recovery.
Experimental Protocol 1: Effect of airial natriuretic factor on hypertonic saline-induced reductions in renal hemodynamics. Following stabilization, two 15-minute baseline clearances which were meaned for data analysis, were obtained for the measurement of renal hemodynamics. Saline vehicle (HS + VEH, N = 6) or ANF (HS + ANF, 100 nglkglmin, N = 6, Penninsula Laboratories, Belmont, California, USA) was then administered directly into the renal artery at 1.2 mI/mm. The atrial peptide used was the 28 amino acid ah-ANF. Fifteen minutes after initiation of this infusion, a 15-minute control clearance was obtained, documenting any changes due to VEH or ANF. The infusion of VEH or ANF was then continued and a 10-minute hypertonic saline infusion (16.2% i.r.) was initiated. The infusion rate of HS was adjusted relative to changes in renal blood flow as previously described by Heidemann et a! using a Harvard 906 variable rate infusion pump to maintain a constant estimated 30 mEq/liter increase in plasma sodium concentration [10] . After five minutes of HS infusion, with the stabilization of urine flow, a five minute clearance was obtained. HS was then discontinued and 15 minutes later, ANF or VEH was stopped. After an additional 15 minutes, a 15-minute recovery clearance was obtained. All solutions for this protocol were made in isotonic saline.
Protocol 2: Effect of atrial natriuretic factor on adenosinemediated reductions in renal hemodynamics. This protocol substituted adenosine for hypertonic saline. Because the renal response to adenosine is more pronounced in volume depleted animals, these experiments were performed on animals that had previously been given a single injection of furosemide (40 mg i.m.) and then maintained on a diet of 447 gm of HD chow (Hills, Topeka, Kansas, USA) with 5 mEq sodium administered daily for at least five days prior to the acute experiment. As a result, urine flows were diminished and longer clearance periods were required to ensure accurate GFR determination.
Additionally, isotonic dextrose (5.5 mg/dl) was substituted for isotonic saline as the vehicle in all solutions to prevent sodium repletion. As in protocol 1, following stabilization, two baseline clearances were obtained except each was 30 minutes in duration. Following baseline clearances, dextrose vehicle (AD + DEX, N 6) or ANF (AD + ANF, N 6) was administered at 1.2 mi/mm (i.r.). Fifteen minutes after initiation of this infusion, a control clearance was obtained documenting any changes due to ANF or DEX. The infusion of vehicle or ANF was then continued as adenosine (0.1 molIliter) was infused at 1.0 mi/mm (i.r.) for 20 minutes, a dose previously documented to result in reproducible reduction in GFR [11] . After 10 minutes of AD infusion, a 10 minute clearance was obtained. AD was then discontinued and 10 minutes later, ANF or DEX was stopped. After an additional 10 minutes, a 10-minute recovery clearance was obtained. All solutions used in this protocol were made in dextrose.
Glomerular filtration rate was measured by the clearance of inulin. Inulin concentrations were measured by the anthrone method [121. Sodium and potassium were measured using ion-selective electrodes (Beckman E2A analyzer, Beckman Instruments, Fullerton, California, USA).
All data from the clearances in baseline, control, hypertonic saline, adenosine, and recovery periods were averaged and are expressed as mean SE. The data were analyzed using Dunnett's paired t-test for simultaneous and multiple comparisons.
Results
Renal hemodynamic and excretory function were measured during baseline, control (vehicle or ANF infusion), HS or AD infusion, and recovery periods, and are summarized in Tables 1  and 2. Protocol I Hypertonic saline alone (HS + VEH. Compared to baseline and control periods, dogs receiving HS alone demonstrated marked reductions in GFR and RBF. Urine flow rate and urinary sodium excretion tended to increase, although these changes were not significant. Urine osmolality decreased and mean arterial blood pressure remained stable.
Hypertonic saline with ANF (HS + ANF,)
Compared to baseline, ANF resulted in significant increases in GFR and no change in RBF. HS decreased GFR but this reduction in GFR was significantly less than when hypertonic saline was infused with vehicle ( Fig. 1) . The changes in RBF in this group were not significant, although a transient vasodilation was observed when the ANF infusion was initiated, consistent with previous observations from this laboratory [131, and there was a tendency for RBF to increase during the hypertonic saline infusion. Representative RBF responses of dogs in each of the two groups receiving hypertonic saline are depicted in Figure 2 . MAP was unchanged between periods in this group. Sodium excretion and urine flow increased in the control and HS infusions periods. U0sm was decreased with the ANF infusion. (Fig. 3) . RBF tended to increase above control values after three to five minutes of AD infusion. Urine flow increased. Urine osmolality tended to decrease after baseline but was significantly decreased only during AD infusion. Mean arterial pressure and urinary sodium excretion did not change during any of the periods.
Adenosine with ANF (AD + ANF). ANF produced an increase in GFR from baseline values that persisted throughout the experiment. AD decreased GFR but this reduction was significantly less than when AD was infused without ANF (Fig.  1) . RBF remained stable from baseline to control periods. With the AD infusion, ANF significantly attenuated the decrease in RBF (AD -54.5 3.6 vs. AD + ANF, -3.7 8.1 mllmin, P < 0.05) followed by a sustained increase (Fig. 3) . Arterial pressure and urine osmolality decreased with ANF infusion and remained depressed throughout the experiment. Urine flow and sodium excretion increased with ANF and remained elevated throughout the experiment.
Discussion
The present studies demonstrate that administration of hypertonic saline (HS) into the renal artery results in a transient renal vasodilatation followed by a decrease in renal blood flow (RBF). This renal vasoconstrictor response was associated with a reversible decrease in glomerular filtration rate (GFR). Administration of pharmacologic concentrations of ANF during infusion of HS attenuated both the renal vasoconstriction and decrease in GFR. The present studies also demonstrate that infusion into the renal artery of adenosine (AD), which has been postulated to be a possible metabolic mediator of TGF [9, 11, 14] , results in a transient renal vasoconstriction followed by a decrease in GFR which is also attenuated by ANF. These studies thus demonstrate that pharmacologic concentrations of ANF block HS-and AD-mediated decreases in RBF and GFR 400 400 -IL and support a modulating role for exogenous ANF in the TGF phenomenon as activated by hypertonic saline.
Aortic administration of HS above the renal arteries or increasing rates of loop perfusion have resulted in reductions in single nephron glomerular filtration rate and/or stop flow pressure as determined by cortical micropuncture studies [3, 6] . Renal arterial administration of HS in the dog have extended this phenomenon to the whole kidney and documented parallel reductions in RBF and GFR [8, 10] . Such investigations have supported the concept of a TGF autoregulatory phenomenon which participates in the regulation of GFR in response to increased delivery of sodium chloride to the macula densa. States of acute and chronic intravascular volume expansion decrease TGF sensitivity in contrast to an enhanced sensitivity in states of acute or chronic volume contraction.
While redundant factors involved with volume homeostasis have been implicated in the modulation of TGF sensitivity, ANF has emerged as a physiologic regulator of cardiorenal homeostasis which could serve as a modulator of TGF sensitivity [15, 16] . Briggs et al reported that high concentrations of crude atrial extract attenuated TGF-mediated reduction in stop flow pressure [5] . More recently, Huang and Cogan have demonstrated with loop microperfusion that maximal TGFmediated reductions in SNGFR are also attenuated by highdose ANF [4] . While these studies support at the single nephron level a role for ANF in attenuating TGF-mediated reductions in SNGFR and/or SFP during high rate single nephron infusion of artificial tubular fluid, the ability of ANF to attenuate whole kidney GFR and specifically TGF-mediated reductions in RBF has not been investigated. The present studies thus confirm and extend to the whole kidney level these previous investigations and demonstrate that pharmacologic concentrations of ANF inhibit both HS-and AD-induced reductions in RBF and GFR at the level of the whole kidney.
The mechanism(s) by which ANF inhibits the HS-mediated decreases in RBF and GFR could be upon inhibition of either the sensor or the effector limb of the TGF phenomenon. High concentrations of intraluminal ANF could desensitize sensing mechanisms at the site of the macula densa. An alternative mechanism may be that intrarenal ANF serves to inhibit the effector limb by inhibiting afferent arteriolar vasoconstriction, thereby preserving glomerular hydrostatic pressure, GFR, and renal blood flow.
Previous studies have supported a role for adenosine as a potential metabolic mediator of TGF [9, 11, 141 . Such studies have speculated that increases in solute delivery to the macula densa with increased solute transport results in increases in adenosine concentration in the tissue adjacent to the afferent vessels. An increase in interstitial adenosine alone or in asso- ciation with other intrarenal vasoconstrictors such as angiotensin II could mediate increases in the resistance of the afferent arteriole [17] . Studies have also supported an action of adenosine to induce mesangial contraction via a specific A1-type receptor, thus decreasing the ultrafiltration coefficient, K [14] .
Our studies demonstrate that ANF antagonizes the hemodynamic action of adenosine to decrease RBF and GFR. While the current study addresses the modulating action of pharmacologic concentrations of ANF which may not be relevant to physiologic concentrations, one may speculate that based upon previous and present observations, ANF may serve to inhibit TGF activation both at the single nephron and at the level of the whole kidney. This action of ANF may be, in part, via a direct hemodynamic action upon the afferent arteriole which antagonizes TGF-mediated decreases in RBF occurring in response to the generation of metabolically active metabolites of adenosine stimulated during TGF-activation.
Other pharmacologic agents such as calcium antagonists and converting enzyme inhibitors may also inhibit TGF-mediated decreases in renal hemodynamics [18, 19] . Thus, while ANF may not serve as a lone antagonist to TGF, it may represent an endogenous circulating inhibitor of TGF in the regulation of glomerular filtration rate. Indeed, increasing evidence continues to emerge that in pathophysiologic states of intravascular volume expansion such as to congestive heart failure with elevated endogenous atrial peptide, ANF serves to preserve glomerular filtration rate [20] [21] [22] .
Others have speculated that in states such as acute tubular necrosis, enhanced solute delivery to the macula densa may activate tubuloglomerular feedback which may augment reductions in GFR [23, 241 . Recently, studies have demonstrated a therapeutic role for pharmacologic concentrations of ANF to restore GFR in models of acute renal failure [25, 261 . While such actions of ANF at pharmacologic concentrations to restore GFR in acute renal failure may represent direct effects upon glomerular dynamics, an inhibition of TGF could be an additional mechanism.
In summary, the present findings demonstrate at the whole kidney level that ANF attenuates HS-induced reductions in RBF and GFR. This study further demonstrates that ANF also attenuates adenosine-mediated reductions in GFR. These studies support a modulating role for pharmacologic concentrations of ANF in the regulation of RBF and GFR responses to tubuloglomerular feedback control of renal blood flow and glomerular filtration.
